Navigation Links
Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinson's Disease With Brain Stimulation During Sleep
Date:7/22/2013

VALLEY VIEW, Ohio, July 22, 2013 /PRNewswire/ -- Great Lakes NeuroTechnologies announced today they have received allowance of claims from the U.S. Patent Office for an application covering their system and method of stimulating the brain during sleep to treat movement disorder symptoms. The claims cover a system and method including a wearable apparatus to position an array of electrodes on the surface of the scalp, provide low dose stimulation to the brain using transcranial direct current stimulation (tDCS), and delivering this stimulation during different stages of sleep. While deep brain stimulation has shown efficacy for treating movement disorders such as Parkinson's disease, non-invasive technologies such as tDCS may provide additional options for patients. Delivering stimulation therapy during sleep may target brain states likely to improve motor symptoms, as well as minimize patient burden since the therapy would occur while they are sleeping.

"While most of our previous work has focused on diagnostics for Parkinson's disease, we also recognize new opportunities for therapy could have a significant impact on patient quality of life." says Dustin Heldman, PhD, Principal Investigator and Biomedical Research Manager. To address the growing movement disorders market, Great Lakes NeuroTechnologies has been committed to the commercialization of its Kinesia [ http://glneurotech.com/kinesia/proview/ ] medical technology platforms. "There is evidence that treating the brain with transcranial direct current stimulation using a non-invasive system can improve Parkinson's symptoms. While current approaches aim to target the location of stimulation to the brain, this approach is targeting the timing of stimulation, by delivering it during sleep." Dr. Heldman also thanked the National Institute of Neurological Disorders and Stroke and the National Institute on Aging for their continued support of these technologies. An ongoing Phase I clinical study (1R43NS077652-01) is evaluating efficacy of the technology in patients.

Great Lakes NeuroTechnologies is committed to building its intellectual property portfolio with new applications stemming from many on-going clinical studies. "These allowed patent claims continue to build on our success in applying for and securing intellectual property for our innovative product and services pipeline targeted toward movement disorders. Strategically, it also represents a bifurcated shift in our portfolio to cover not only diagnostics but certain therapies that leverage key components of our diagnostic technology", says Brian Kolkowski, PhD, Executive Vice-President and General Counsel. "As our technology continues to grow commercially in both domestic and international markets, our growing patent portfolio will help to provide strategic advantage for our company by protecting technology in our targeted markets."

About Great Lakes NeuroTechnologies
Great Lakes NeuroTechnologies [ http://www.glneurotech.com ] is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.

Media Contact
Amelia Earhart, 216-361-5410 - aaearhart@GLNeuroTech.com

 



 

 


'/>"/>
SOURCE Great Lakes NeuroTechnologies
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master Service Agreement to Offer Clients Greater Access to Global Central Lab Services
2. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
3. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
4. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
5. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
6. Breakthrough "AffloVest" Greatly Advances Respiratory Care
7. A Greater Effect on Depressive Symptoms than Current Treatments is One of the Greatest Unmet Needs in Treatment-Resistant Depression
8. Smart911 and In Case of Emergency Standard Partner to Enhance Availability of Life Saving Data for Greater Emergency Response
9. Cancer drug shortages mean higher costs and greater risk for patients
10. The 113th Canton Fair: "Great Opportunities for Emerging Markets"
11. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):